Cologne/Berlin, Germany and Boston, MA, USA, September 1, 2022 – InfanDx AG, a privately held diagnostics company focused on the development and commercialization of new diagnostic solutions for infants, announced today that it has appointed Ms. Nicole Witzmann as Chief Financial Officer (CFO) effective September 1, 2022.
Ms. Witzmann has more than eight years of experience in corporate finance in the healthcare sector and joins from Adrenomed AG, where he served for several years as Head of Finance. As financial director, Ms. Witzmann will be responsible for general administration, accounting and control, financial reporting and, together with CEO Dr. Achim Plum, investor relations and fundraising. The company is currently preparing a Series B financing round, which is expected to close in late 2022 or early 2023 based on significant value creation milestones, such as clinical validation of the biomarker panel HypoxE® which is expected to be completed in the coming weeks.
Ms. Witzmann will take over from Dr. Andreas Lischka, who has led the finance department of InfanDx as an external advisor since January 2021. Although Dr. Lischka will leave the company at his own request to pursue other opportunities, he will remain available for an extended period. period to ensure a smooth transition to Ms. Witzmann.
“We are very pleased to have Nicole join our management team,” commented Dr. Achim Plum, CEO of InfanDx. “Having worked with her for some time in a previous position, I am confident that she will add exactly the skills and experience we need to further develop InfanDx into a fully integrated diagnostics company that delivers innovation for acute and critical care I would also like to take this opportunity to wholeheartedly thank Dr. Lischka for his services to InfanDx which were invaluable in repositioning and growing the company since I took over as CEO in January 2021.”
“I am very honored to be a part of InfanDx’s management team going forward,” said Nicole Witzmann. “As a mother of three, with my youngest son born just a few months ago, I feel particularly close to InfanDx’s vision and mission. I am excited and eager to help bring the InfanDx HypoxE test to hypoxic-ischemic encephalopathy to the market as it has the opportunity to prevent serious and lasting injury to children affected by oxygen deprivation during delivery.”
InfanDx AG is a privately held company that focuses on the development and commercialization of new diagnostic solutions for acute and critical care conditions in neonates.
The company’s patented lead product in clinical development is the InfanDx HypoxE® test designed for the reliable identification of hypoxic-ischemic encephalopathy (HIE) during the first hours of life. HIE as a result of perinatal asphyxia (lack of oxygen during childbirth) can lead to lifelong disabilities. The long-term detrimental effects of HIE can be mitigated and even prevented by neuroprotective hypothermia treatment. However, this therapy must be initiated within six hours of birth to be effective, and they require appropriate diagnostic methods to reliably and timely identify affected neonates. Although standard-of-care diagnostic methods cannot provide a conclusive diagnosis of HIE in this time frame, the InfanDx HypoxE® Rapid Test is designed to support clinicians in the timely decision of whether newborns require treatment of ‘neuroprotective hypothermia.
The company is headquartered in Cologne, Germany, with a branch office in Berlin, Germany, and a wholly owned subsidiary in Boston, MA, USA.
For more information, visit: http://www.infandx.com/
For more information about InfanDx, please contact:
Nathaly Schaefer, Director of Corporate Affairs
Q: +49 (0) 30 556 535 81
InfanDx USA, Inc.
Jordan deVos (VP of Operations)
Contact with the media
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68